Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Chronic lymphocytic leukaemia, first treatment, drawn from the whole corpus: 30 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Continuous BTK inhibitor or fixed-duration venetoclax first: no head-to-head survival data.
Whether MRD should decide how long fixed-duration therapy lasts.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Cardiac toxicity, cost and interactions of indefinite BTK inhibition in patients in their seventies and eighties.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 20 changes by month →When this page itself was last checked or edited.
Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)
A milestone in how this cancer is treated.
3-year PFS 76.
Ibrutinib delayed progression to symptomatic disease but did not improve survival: five-year overall survival 93.
5-year PFS 81.